Evidence map›Paper›PMID 36539061›Full record

ArticleContemporary clinical trials2023

Best practices to reduce COVID-19 in group homes for individuals with serious mental illness and intellectual and developmental disabilities: Protocol for a hybrid type 1 effectiveness-implementation cluster randomized trial.

Julie H Levison, David Krane, Karen Donelan, Kelly Aschbrenner, Hao D Trieu, Cindy Chau, Anna Wilson, Nicolas M Oreskovic, Kelly Irwin, Lisa I Iezzoni and 13 more

Registry-linked trialOpen access · greenAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04726371 (Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04726371 nacompletednot on this map

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

TypeinterventionalSponsorMassachusetts General HospitalRan2020 to 2022Enrolled415ConditionsIntellectual Disability, Developmental Disability, Axis I Diagnosis, Mental IllnessArmsGeneric Best Practices, Tailored Best Practices
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Tailored interventions to address determinants of practice.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Julie H LevisonHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA; Harvard Medical School, Massachusetts General Hospital, Department of Medicine, 55 Fruit St, Gray 7-730, Boston, MA 02114, USA. Electronic address: jlevison@partners.org.
David KraneHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Karen DonelanHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Kelly AschbrennerGeisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Department of Psychiatry, One Medical Center Drive, Lebanon, NH 03756, USA.
Hao D TrieuHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Cindy ChauHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Anna WilsonHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Nicolas M OreskovicHarvard Medical School, Massachusetts General Hospital, Department of Medicine, 55 Fruit St, Gray 7-730, Boston, MA 02114, USA; Harvard Medical School, Massachusetts General Hospital, Department of Pediatrics, Division of Medical Genetics and Metabolism, Down Syndrome Program, 125 Nashua Street, Suite 821, Boston, MA 02114, USA.
Kelly IrwinHarvard Medical School, Massachusetts General Hospital, Department of Psychiatry, 55 Fruit Street, Boston, MA 02114, USA.
Lisa I IezzoniHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Haiyi XieGeisel School of Medicine at Dartmouth, Department of Biomedical Data Science, Williamson Translational Research Building, Third Floor, HB 7261, 1 Medical Center Drive, Lebanon, NH 03756, USA.
Ronita SamuelsHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA.
Paula SilvermanVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Joey BatsonVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Ahmed FathiVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Stefanie GamseVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Sibyl HollandVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Jessica WolfeVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Kim ShellenbergerVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Elizabeth CellaVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Bruce BirdVinfen Corporation, 950 Cambridge Street, Cambridge, MA 02141, USA.
Brian G SkotkoHarvard Medical School, Massachusetts General Hospital, Department of Pediatrics, Division of Medical Genetics and Metabolism, Down Syndrome Program, 125 Nashua Street, Suite 821, Boston, MA 02114, USA; Harvard Medical School, Massachusetts General Hospital, Department of Pediatrics, 55 Fruit Street, Boston, MA 02214, USA.
Stephen BartelsHarvard Medical School, Massachusetts General Hospital, Mongan Institute, 100 Cambridge St, Suite 1600, Boston, MA 02114, USA; Harvard Medical School, Massachusetts General Hospital, Department of Medicine, 55 Fruit St, Gray 7-730, Boston, MA 02114, USA.
Massachusetts General Hospital · USDartmouth College · USDartmouth–Hitchcock Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople with serious mental illness (SMI) and intellectual disabilities and/or developmental disabilities (ID/DD) living in group homes (GHs) and residential staff are at higher risk for COVID-19 infection, hospitalization, and death compared with the general population.

methodsWe describe a hybrid type 1 effectiveness-implementation cluster randomized trial to assess evidence-based infection prevention practices to prevent COVID-19 for residents with SMI or ID/DD and the staff in GHs. The trial will use a cluster randomized design in 400 state-funded GHs in Massachusetts for adults with SMI or ID/DD to compare effectiveness and implementation of "Tailored Best Practices" (TBP) consisting of evidence-based COVID-19 infection prevention practices adapted for residents with SMI and ID/DD and GH staff; to "General Best Practices" (GBP), consisting of required standard of care reflecting state and federal standard general guidelines for COVID-19 prevention in GHs. External (i.e., community-based research staff) and internal (i.e., GH staff leadership) personnel will facilitate implementation of TBP. The primary effectiveness outcome is incident SARS-CoV-2 infection and secondary effectiveness outcomes include COVID-19-related hospitalizations and mortality in GHs. The primary implementation outcomes are fidelity to TBP and rates of COVID-19 vaccination. Secondary implementation outcomes are adoption, adaptation, reach, and maintenance. Outcomes will be assessed at baseline, 3-, 6-, 9-, 12-, and 15-months post-randomization.

conclusionsThis study will advance knowledge on comparative effectiveness and implementation of two different strategies to prevent COVID-19-related infection, morbidity, and mortality and promote fidelity and adoption of these interventions in high-risk GHs for residents with SMI or ID/DD and staff. CLINICAL TRIAL REGISTRATION NUMBER: NCT04726371.

Indexed as

COVID-19AdultChildCOVID-19 VaccinesDevelopmental DisabilitiesGroup HomesHumansRandomized Controlled Trials as TopicSARS-CoV-2COVID-19 VaccinesCoronavirusCOVID-19Developmental disabilitiesGroup homesIntellectual disabilitiesSerious mental illness

Identifiers

PMID36539061
PMCPMC9758744
OpenAlexW4312115104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.